subscribeSubscribe
Novartis gears up for key expansions of 3 cancer drugs

Novartis gears up for key expansions of 3 cancer drugs
Angus Liu FIERCE PHARMA
24 Apr 2024
Share Share
Novartis Scemblix shows superior MMR rates vs. TKIs in Phase III trial

Novartis Scemblix shows superior MMR rates vs. TKIs in Phase III trial
GLOBENEWSWIRE
08 Jan 2024
Share Share
Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix

Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix
GLOBENEWSWIRE
20 Nov 2023
Share Share
Scemblix`s Scemblix (asciminib) Receives Approval in Europe

Scemblix`s Scemblix (asciminib) Receives Approval in Europe
EMA
02 Mar 2023
Share Share
Novartis`s Scemblix (asciminib) Receives Approval in Europe

Novartis`s Scemblix (asciminib) Receives Approval in Europe
EMA
07 Sep 2022
Share Share
Scemblix™, a first-in-class CML treatment with new mechanism of action approved

Scemblix™, a first-in-class CML treatment with new mechanism of action approved
NEWSWIRE
31 Aug 2022
Share Share
Novartis receives vital licence for Scemblix

Novartis receives vital licence for Scemblix
John Pinching PHARMATIMES
17 Jun 2022
Share Share
Access to Novartis treatment for Myeloid leukaemia patients

Access to Novartis treatment for Myeloid leukaemia patients
PHARMATIMES
25 Jan 2022
Share Share
Novartis scores new CML OK for `wild card` STAMP inhibitor

Novartis scores new CML OK for `wild card` STAMP inhibitor
Amber Tong ENDPTS
30 Oct 2021
Share Share
FDA approves Novartis Scemblix® (asciminib), with novel MOA

FDA approves Novartis Scemblix® (asciminib), with novel MOA
NOVARTIS
29 Oct 2021
Share Share